{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:04:09Z","timestamp":1760123049694,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Novel coronavirus disease 2019 has been stated as global disease pandemic due to its rapid spread worldwide. Up to 30% of coronavirus disease 2019 patients with hypertension are more susceptible to death. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been used as primary line of medication for hypertension; nonetheless, conflicting data arises as numerous studies showed contradictory results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Aiming to show clinical outcome of renin-angiotensin-aldosterone system blockers in hospital treatment of hypertensive patients with coronavirus disease 2019, systematically searched literatures through five databases were intensively appraised using <jats:italic>The Grading of Recommendations Assessment<\/jats:italic>, <jats:italic>Development and Evaluation<\/jats:italic> checklists for cohort studies. Based on the result evaluation from retrospective cohorts involving more than 15,000 patients across Asia and other regions of the world, ten encompassed studies divided into two subgroups in this meta-review showed that in-hospital hypertensive coronavirus disease 2019 patients receiving antihypertensive drugs were associated with overall risk reduction in subgroup 1 (hazard ratio, HR = 0.96, 95% CI = 0.82\u20131.12) to no outcome association of all-cause mortalities in subgroup 2 (HR = 0.26, 95% CI = 0.19\u20130.34). All appraised studies in synergism showed that mortality outcomes were not augmented with the employment of either ACE inhibitor or ARB in subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Therefore, the results support recommendation by the American Heart Association not to discontinue angiotensin-converting enzyme inhibitor or angiotensin receptor blocker regimens in coronavirus disease 2019 patients with hypertension.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-021-00135-y","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:09:02Z","timestamp":1612526942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-2758","authenticated-orcid":false,"given":"Andrea","family":"Laurentius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radityo","family":"Prakoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"135_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708\u20131720","journal-title":"N Engl J Med"},{"key":"135_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Respir Med 395:497\u2013506","journal-title":"Lancet Respir Med"},{"key":"135_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","volume":"30","author":"JM Flack","year":"2020","unstructured":"Flack JM, Adekola B (2020) Blood pressure and the new ACC\/AHA hypertension guidelines. Trends Cardiovasc Med 30:160\u2013164","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"135_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffman","year":"2020","unstructured":"Hoffman M, Kleine-Weber H, Schroeder S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271\u2013280","journal-title":"Cell"},{"issue":"2","key":"135_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281\u2013292","journal-title":"Cell"},{"issue":"4","key":"135_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8(4):21","journal-title":"Lancet Respir Med"},{"issue":"8","key":"135_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11(8):875\u2013879","journal-title":"Nat Med"},{"issue":"3","key":"135_CR8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1542\/peds.2017-2151","volume":"140","author":"A Hardin","year":"2017","unstructured":"Hardin A, Hackell J (2017) Age limit of pediatrics. Pediatrics 140(3):2017\u20132151","journal-title":"Pediatrics"},{"key":"135_CR9","unstructured":"Diagnostic testing and screening for SARS-CoV-2 (2020) European Centre for Disease Prevention and Control. Available from: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/latest-evidence\/diagnostic-testing. Accessed 4 May 2020"},{"key":"135_CR10","unstructured":"WHO Interim guidance (2020) World Health Organization. https:\/\/www.who.int\/publications-detail\/laboratory-testing-for-2019-novel-coronavirus-in-suspectedhuman-cases-20200117. Accessed 4 May 2020."},{"key":"135_CR11","doi-asserted-by":"publisher","unstructured":"Meader N, King K, Llewellyn A (2014) A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. https:\/\/doi.org\/10.1186\/2046-4053-3-82","DOI":"10.1186\/2046-4053-3-82"},{"issue":"7","key":"135_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 5(7):825\u2013830","journal-title":"JAMA Cardiol"},{"key":"135_CR13","doi-asserted-by":"crossref","unstructured":"Lee H, Ahn J, Kang C (2020) Association of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19 related outcome. Res Sq Preprint at doi: 10.21203\/rs.3.rs-29483\/v1.","DOI":"10.21203\/rs.3.rs-29483\/v1"},{"key":"135_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1056\/NEJMoa2007621","volume":"382","author":"M Mehra","year":"2020","unstructured":"Mehra M, Desai S, Kuy S (2020) Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med 382:102","journal-title":"N Engl J Med"},{"issue":"25","key":"135_CR15","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"H Reynolds","year":"2020","unstructured":"Reynolds H, Adhikari S, Pulgarin C (2020) Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19. N Engl J Med 382(25):2441\u20132448","journal-title":"N Engl J Med"},{"issue":"2","key":"135_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"E Fosbol","year":"2020","unstructured":"Fosbol E, Butt J, Ostergaard L (2020) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA Cardiol 324(2):168\u2013177. https:\/\/doi.org\/10.1001\/jama.2020.11301","journal-title":"JAMA Cardiol"},{"issue":"1","key":"135_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9(1):757\u2013760","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"135_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/10641963.2020.1764018","volume":"42","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zhu J, Xu T (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin\u2013angiotensin system inhibitors. Ann Clin Exp Hypertens 42(7):656\u2013660","journal-title":"Ann Clin Exp Hypertens"},{"key":"135_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126:1671\u20131681","journal-title":"Circ Res"},{"key":"135_CR20","doi-asserted-by":"publisher","unstructured":"Yang G, Tan Z, Zhou L (2020) Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. MedRxiv. Preprint at doi: https:\/\/doi.org\/10.1101\/2020.03.31.20038935.","DOI":"10.1101\/2020.03.31.20038935"},{"issue":"3","key":"135_CR21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/HYPERTENSIONAHA.120.15289","volume":"76","author":"W Pan","year":"2020","unstructured":"Pan W, Zhang J, Wang M (2020) Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients. Hypertension 76(3):732\u2013741","journal-title":"Hypertension"},{"key":"135_CR22","unstructured":"PRISMA Flow Diagram (2015) PRISMA Statement. http:\/\/prisma-statement.org\/PRISMAStatement\/FlowDiagram. Accessed 9 May 2020."},{"issue":"8","key":"135_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s42399-020-00363-4","volume":"2","author":"A Sanyaolu","year":"2020","unstructured":"Sanyaolu A, Okorie C, Marinkovic A (2020) Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2(8):1069\u20131076","journal-title":"SN Compr Clin Med"},{"issue":"13","key":"135_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA Cardiol 323(13):1239\u20131242. https:\/\/doi.org\/10.1001\/jama.2020.2648","journal-title":"JAMA Cardiol"},{"key":"135_CR25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T et al (2020) Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653\u20131659","journal-title":"N Engl J Med"},{"key":"135_CR26","unstructured":"American Heart Association (AHA) Guidance (2020) American Heart Association Newsroom. https:\/\/newsroom.heart.org\/news\/what-people-with-high-blood-pressure-need-to-know-about-covid-19. Accessed 9 May 2020."},{"key":"135_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C et al (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 63:364\u2013374","journal-title":"Sci China Life Sci"},{"issue":"5","key":"135_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S2213-2600(20)30153-3","volume":"8","author":"CJ Tignanelli","year":"2020","unstructured":"Tignanelli CJ, Ingraham NE, Sparks MA et al (2020) Antihypertensive drugs and risk of COVID-19? Lancet Respir Med 8(5):30\u201331","journal-title":"Lancet Respir Med"},{"key":"135_CR29","unstructured":"Chow N, Dutra KF, Gierke R (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -- United States, February 12-March 28, 2020. In: Morbidity and mortality weekly report. Center for Disease Control and Prevention. Available via DIALOG. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6913e2.htm of subordinate document. Accessed 6 May 2020."},{"issue":"12","key":"135_CR30","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1258\/ebm.2012.012123","volume":"237","author":"X Wang","year":"2012","unstructured":"Wang X, Khaidakov M, Ding Z et al (2012) Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. Exp Biol Med 237(12):1394\u20131401","journal-title":"Exp Biol Med"},{"issue":"2","key":"135_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","volume":"7","author":"M Richardson","year":"2019","unstructured":"Richardson M, Garner P, Donegan S (2019) Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health 7(2):192\u2013198","journal-title":"Clin Epidemiol Glob Health"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s43044-021-00135-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:28:49Z","timestamp":1612528129000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-021-00135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1186\/s43044-021-00135-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. No ethical approval will be needed because data from previous published studies in which informed consent was obtained by primary investigators will be retrieved and analyzed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Written informed consent for publication was not necessary because no patient data has been included in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors hereby declare that they have no competing interest and other potentially conflicting interests, including specific financial interests and relationships and affiliations relevant to the Egyptian Heart Journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}